Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q3

4583.TEDINET S100PLJL
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥434m2022-01-01 → 2022-09-30StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥542m2021-01-01 → 2021-09-30StandaloneNet sales
Operating income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOperating income
Operating income−¥851m2021-01-01 → 2021-09-30StandaloneOperating income
Ordinary income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥843m2021-01-01 → 2021-09-30StandaloneOrdinary income
Profit before tax−¥1.0bn2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Profit before tax−¥830m2021-01-01 → 2021-09-30StandaloneIncome before income taxes
Net income−¥1.0bn2022-01-01 → 2022-09-30StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥843m2021-01-01 → 2021-09-30StandaloneProfit loss
Total assets¥2.1bnat 2022-09-30StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.0bnat 2021-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥431mat 2022-09-30StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.7bnat 2022-09-30StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.4bnat 2021-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.6bnat 2022-09-30StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-23.872022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-20.942021-01-01 → 2021-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.772021-07-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio78.4%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.6%at 2021-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued45,979,100at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,305,500at 2021-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥358m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥916m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥681m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥328m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-09-30−¥757m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥523m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 325
ItemContextValueUnit
Investments and other assetsCurrentQuarterInstant_NonConsolidatedMember122821000JPY
Noncurrent assetsPrior1YearInstant_NonConsolidatedMember122555000JPY
Noncurrent assetsCurrentQuarterInstant_NonConsolidatedMember125615000JPY
AssetsPrior1YearInstant_NonConsolidatedMember2339439000JPY
AssetsCurrentQuarterInstant_NonConsolidatedMember2081453000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember29809000JPY
Accounts payable tradeCurrentQuarterInstant_NonConsolidatedMember42938000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember183000000JPY
Short term loans payableCurrentQuarterInstant_NonConsolidatedMember188000000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember81549000JPY
Accounts payable otherCurrentQuarterInstant_NonConsolidatedMember62887000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember39636000JPY
Accrued expensesCurrentQuarterInstant_NonConsolidatedMember27636000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember16745000JPY
Income taxes payableCurrentQuarterInstant_NonConsolidatedMember12698000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember30523000JPY
Advances receivedCurrentQuarterInstant_NonConsolidatedMember31700000JPY
Contract liabilitiesPrior1YearInstant_NonConsolidatedMember－JPY
Contract liabilitiesCurrentQuarterInstant_NonConsolidatedMember1767000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember6453000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember6106000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember4821000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember3175000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember392540000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember376910000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember53849000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54164000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember53849000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54164000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember446390000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember431074000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember1515929000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember1916611000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3115710000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember3516391000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-2773693000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-3801019000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1857654000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1631690000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember35394000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember18687000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1893049000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1650378000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2339439000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember2081453000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember541690000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember433694000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember203898000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass